BioNeex Interview with Co-Founder & CEO of Odylia Therapeutics, Scott Dorfman (Short)

BioNeex Founder, Smbat Rafayelyan sat down with Odylia Therapeutics CEO and co-Founder, Scott Dorfman to discuss Odylia's nonprofit approach to drug development and our lead gene therapy program to treat vision loss caused by mutations in RPGRIP1.
Full interview can be found here: bioneex.com/in...
About Odylia Therapeutics | odylia.org
Odylia is developing a gene therapy to treat vision loss caused by RPGRIP1 mutations. This gene therapy uses the novel Anc80 vector technology, which has a superior delivery profile compared to commonly used AAVs. RPGRIP1 mutations cause a spectrum of vision-related deficits most commonly diagnosed as LCA type 6 (LCA6). LCA6 patients are often completely blind from early childhood and have a rapid decline in photoreceptor function, but it is believed that the treatment window extends into adulthood and there is a potential for the regain of function in intact cells.
About BioNeex | bioneex.com
BioNeex is the first R&D open exchange platform in the biopharma industry. The platform facilitates licensing and co-development partnerships for preclinical and clinical-stage drug candidates between biotech, biopharma companies and research institutions. Additionally, BioNeex initiates investments, acquisitions, joint ventures and other types of collaborations.
In essence, BioNeex provides an online infrastructure for biopharma, biotech companies and research institutions, where they can meet and create R&D partnerships.